Related Experiment Video
Updated: Sep 18, 2025

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
Published on: April 26, 2017
Spliced to kill: RNA mis-splicing derived cancer neoantigens
Anurag V Prabhu1, Carla Azar-Koussa1, Zahava Siegfried1
1Department of Biochemistry and Molecular Biology, IMRIC, Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel.
None:
One of the major challenges in using neoantigen-based approaches in cancer treatment is the identification of cancer-specific neoantigens, particularly those that are shared by patients. In a recent report, Kim et al. uncover a novel source of cancer neoantigens in splicing factor mutant myeloid malignancies. These mis-spliced neoantigens offer new opportunities for engineered TCR-T cell therapies and neoantigen-based vaccines.
Related Concept Videos
RNA Splicing
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Non-LTR Retrotransposons
Cancers Originate from Somatic Mutations in a Single Cell
Induced Pluripotent Stem Cells
Somatic...

